ClinicalTrials.gg
RecruitingNCT07223021Updated Nov 12, 2026

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

A Phase 3 interventional study of Fludarabine and Cyclophosphamide in B-cell Acute Lymphoblastic Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in 3 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 12, 2026First site in GermanySite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies testing fludarabine in Burkitt Lymphoma — 6 open to participants now, 12 under way, 1 of them phase 3. fludarabine · Burkitt Lymphoma.

Planned enrollment
11th of 58
130 · median 38
Started
2025
with 1 other
Phase 3
Only one
of the 58
Primary completion
2028-10
later than 9 of 11 live
Registered
56th of 58
by date
Lead sponsor
2 of 58
Memorial Sloan Kettering Cancer Center

Among the 58 studies testing fludarabine in Burkitt Lymphoma, this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 56th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

6 of the 58 studies testing fludarabine in Burkitt Lymphoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing fludarabine in Burkitt Lymphoma, or all of them as a file.
02

Study summary

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • Fludarabine
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
  • Patient's weight > 9 kg at time of lymphodepleting chemotherapy
  • Adequate organ function at time of LD is required and is defined:

    • Hepatic: Serum ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
    • Hepatic: and ALT \< 5x the for age, unless thought to be leukemic disease-related
    • Renal: Calculated (GFR) ≥ 70 ml/min/1.73m\^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL
    • Cardiac: ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening
    • Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air
  • Adequate performance status:

    • Age ≥ 16 years: ≤ 1 or > 60% at treatment
    • Age \< 16 years: Lansky ≥ 60% at treatment
  • Willing to participate as research subject and provide written from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.

Exclusion criteria

Exclusion Criteria:

  • Have a known immediate or delayed reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel.
  • Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol
  • active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.)
  • Patient/parent/guardian unable to give or unable to comply with the treatment protocol.
  • Pregnant or lactating women
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Active comparator
    Standard Fludarabine regimen followed by CAR-T

    Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4)

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: CAR-T

  • Experimental
    Targeted fludarabine regimen followed by CAR-T

    Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg\*h/L (range 17.5-18.5mg\*h/L

    Drug: Cyclophosphamide · Drug: Fludarabine · Biological: CAR-T

Interventions

  • Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4)

  • All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6).

  • Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg\*h/L (range 17.5-18.5mg\*h/L)

  • BiologicalCAR-T

    will be infused based on institutional guidelines.

06

What researchers measure

Primary outcomes

  1. compare the event free survival (EFS )

    EFS is defined as time from randomization until non-response at day 28 after CAR T cell infusion, loss of B-cell aplasia \<6 months from the time of CAR T cell infusion, disease relapse, initiation of anti-leukemic therapy or death of any cause

    Time frame: 28 days

Secondary outcomes

  1. survival

    Time frame: 2 years

07

Study locations

6 of 7 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Kevin Curran, MD · Contact1-833-MSK-KIDS
    • Jaap Jan Boelens, MD,PhD · Contact1-833-MSK-KIDS
    • Kevin Curran, MD · Principal investigator
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Christine Phillips, MD · Contact513-636-4266
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Regina Myers, MD · Contact267-426-0762
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
    Not yet recruiting
    • Aimee Talleur, MD · Contact901-595-4215
  • Texas Children's Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Rayne Rouce, M.D., B.S. · Contact832-822-4242
  • University Children's Hospital Münster
    Münster, Germany
    Recruiting
    • Claudia Rossig, MD · Contact+49 17641091917
  • Prinses Máxima Centrum
    Utrecht, Netherlands
    Recruiting
    • Friso Calkoen, MD · Contact+31 88 972 7272
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 19 phase 3 interventional studies under Burkitt Lymphoma, half reached primary completion within 106 months of starting (the median), counting those still running; a quarter within 78 and three quarters within 119. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 31, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 8 sites removed — first site in Germany. 2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Texas Children's Hospital (Data Collection) · Houston, United StatesNot yet recruiting→Recruiting
  • St. Jude Children's Research Hospital · Memphis, United StatesRecruiting→Not yet recruiting
Show 9 added (5 United States, 2 Germany, 2 Netherlands)
  • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
  • Children's Hospital of Philadelphia · Philadelphia, United States
  • St. Jude Children's Research Hospital · Memphis, United States
  • Baylor College Medical Center · Houston, United States
  • Texas Children's Hospital · Houston, United States
  • University Children's Hospital Münster (Data Analysis) · Münster, Germany
  • Prinses Máxima Centrum (Data Analysis) · Utrecht, Netherlands
  • University Children's Hospital Münster · Münster, Germany
  • Prinses Máxima Centrum · Utrecht, Netherlands
Show 8 removed
  • Cincinnati Children's Hospital Medical Center (Data Collection Only) · Cincinnati, United States
  • Children's Hospital of Philadelphia (Data Collection Only) · Philadelphia, United States
  • Baylor College Medical Center (Data Collection Only) · Houston, United States
  • Texas Children's Hospital (Data Collection) · Houston, United States
  • Prinses Máxima Centrum (Data Collection and Analysis) · Utrecht, Netherlands
  • Baylor College Medical Center · Houston, United States
  • University Children's Hospital Münster (Data Analysis) · Münster, Germany
  • Prinses Máxima Centrum (Data Analysis) · Utrecht, Netherlands
across 3 updates, Oct 5, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    2 sites added, 3 sites removed. St. Jude Children's Research Hospital is now Not yet recruiting
    Show 2 added (1 Germany, 1 Netherlands)
    • University Children's Hospital Münster · Münster, Germany
    • Prinses Máxima Centrum · Utrecht, Netherlands
    Show 3 removed
    • Baylor College Medical Center · Houston, United States
    • University Children's Hospital Münster (Data Analysis) · Münster, Germany
    • Prinses Máxima Centrum (Data Analysis) · Utrecht, Netherlands
    + 1 other change: verification date
  2. Nov 5, 2026
    7 sites added, 5 sites removed — first site in Germany
    Show 7 added (5 United States, 1 Germany, 1 Netherlands)
    • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
    • Children's Hospital of Philadelphia · Philadelphia, United States
    • St. Jude Children's Research Hospital · Memphis, United States
    • Baylor College Medical Center · Houston, United States
    • Texas Children's Hospital · Houston, United States
    • University Children's Hospital Münster (Data Analysis) · Münster, Germany
    • Prinses Máxima Centrum (Data Analysis) · Utrecht, Netherlands
    Show 5 removed
    • Cincinnati Children's Hospital Medical Center (Data Collection Only) · Cincinnati, United States
    • Children's Hospital of Philadelphia (Data Collection Only) · Philadelphia, United States
    • Baylor College Medical Center (Data Collection Only) · Houston, United States
    • Texas Children's Hospital (Data Collection) · Houston, United States
    • Prinses Máxima Centrum (Data Collection and Analysis) · Utrecht, Netherlands
  3. Oct 5, 2026
    Texas Children's Hospital (Data Collection) is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07223021
Collaborators
Princess Maxima Center for Pediatric Oncology
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Oct 20, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Kevin Curran, MD
Contact
currank@mskcc.org
1-833-MSK-KIDS
Jaap Jan Boelens, MD, PhD
Contact
1-833-MSK-KIDS
Kevin Curran, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fludarabine

Start the discussion